VDAC1 and Parkinson disease: In a cellular model of Parkinson’s disease, the dopaminergic cell line SH-SY5Y was exposed to the mitochondrial complex-1 inhibitor rotenone leading to increased VDAC-1 levels [65], while in post-mortal brain tissue, VDAC-1 levels are clearly reduced [35].